Back to Top Skip to main content Skip to sub-navigation

DTRA contributes to historic Ebola vaccine effort

Air Force Staff Sgt. Lee Nembhard, an aeromedical evacuation technician assigned to the 375th Aeromedical Evacuation Squadron from Scott Air Force Base, Illinois, straps a simulated Ebola patient to a litter during a Transport Isolation System training exercise at Joint Base Charleston, South Carolina. (U.S. Air Force photo by Senior Airman Megan Munoz) Air Force Staff Sgt. Lee Nembhard, an aeromedical evacuation technician assigned to the 375th Aeromedical Evacuation Squadron from Scott Air Force Base, Illinois, straps a simulated Ebola patient to a litter during a Transport Isolation System training exercise at Joint Base Charleston, South Carolina. (U.S. Air Force photo by Senior Airman Megan Munoz)

Recommended Content:

Immunization Healthcare | Immunizations | Global Emerging Infections Surveillance | Global Health Engagement | Global Health Engagement

FORT BELVOIR, Va. — The team of researchers and program managers at the Defense Threat Reduction Agency (DTRA) that has worked to counter the threat of the Ebola Virus Disease (EVD) welcomed the announcement of the U.S. Food and Drug Administration’s (FDA) approval of the vaccine, Ervebo ®, to the pharmaceutical company Merck & Co., Inc., December 19, 2019.

The approval of the vaccine represents the culmination of nearly two decades of efforts by a host of teams from across the public and private sectors such as DTRA and Merck, international partners in North America, Europe and Africa, and non-governmental and international organizations. The World Health Organization (WHO) describes EVD as a rare but severe hemorrhagic fever. EVD has killed thousands over the course of outbreaks, primarily in sub-Saharan Africa, since it first appeared in the 1970s.

DTRA, a Department of Defense combat support agency that identifies and combats biological threats as part of its mission to counter weapons of mass destruction (WMD), began its work on the vaccine in 2014 during an especially deadly outbreak in West Africa. The outbreak made clear the danger EVD posed to U.S. national security interests abroad, as well as to the U.S. domestic population in the event of a pandemic. To counter the threat, DTRA quickly initiated a strategy to get a vaccine approved. The combat support agency coordinated a series of investment efforts and partnerships to deliver a baseline platform for a viable vaccine candidate to mitigate the spread of the deadly disease.

“DTRA’s agile contracting, and well-placed contacts throughout government, academia, and industry allowed DTRA to form partnerships and guide development of this vaccine from the early stages of development, through crucial preclinical, and critical phase 1 clinical safety trials to the actual phase 2 clinical efficacy trial that demonstrated effectiveness of this vaccine during the outbreak,” said L. Revell Phillips Ph.D., a member of DTRA’s research and development team.

DTRA’s pioneering approach started with a contract to BioProtection Systems, a small biotech company. DTRA and BioProtection Systems partnered with Public Health Agency Canada, who began developing the vaccine in 2001, to accelerate its development. With these three teams working together, the vaccine progressed to a series of nonclinical and clinical studies conducted at the U.S. Army Medical Research Institute of Infectious Disease (USAMRIID) and Walter Reed Army Institute of Research (WRAIR) defense laboratories.

As the effort evolved, DTRA leveraged its USAMRIID partner’s research capacity, resulting in international partnering agreements with the WHO. DTRA also coordinated with teams across the U.S. government as development of the vaccine progressed. The efforts of this research and development consortium produced viable data that would be transitioned to next-level partners.

“We exercised our ability to develop partnerships for a relevant need, which was critical in transitioning medical countermeasures to our advanced developers at the speed of relevancy,” said Army Maj. Jeffrey Froude, DTRA’s program manager for the EVD Vaccine.

Froude explained that DTRA bolstered its research and development investments through two key U.S. governmental partners. First, DTRA worked closely with the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, for advanced trials and manufacturing activities. Second, DTRA teamed with the DoD’s Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) for the task of immunoassay development. For that development effort, JPEO-CBRND’s, office of the Joint Program Manager for CBRN Medical took the lead.

Following several years of coordinated research and development efforts by the coalition of partners, the promising vaccine candidate transitioned to next-level partners BARDA and Merck for more advanced human clinical trials and product manufacturing of the EVD vaccine.

“This vaccine’s rapid progress is a testament to the power of partnerships among government agencies and with the private sector,” said BARDA director Rick Bright.

Next-level partner BARDA and Merck, served as the transition point to conduct more advanced human clinical trials and product manufacturing on the Ebola vaccine with the Joint Program Executive office (JPEO) providing a testing capability that allowed Merck to test human and non-human primate samples. The Joint Project Manager for Chemical, Biological, Radiological and Nuclear Medical (JPM-CBRN), Army Col. Ryan Eckmeier, stated that this “interagency partnership from the beginning was critical to advancing this vaccine product.”

Merck’s expertise with licensing and manufacturing was instrumental in advancing the vaccine. The pharmaceutical giant partnered with the WHO, United Nations International Children's Emergency Fund, and Gavi Vaccine Alliance, among others, to strategize on how to best implement future public health preparedness and response efforts against EVD.

“We share in this achievement, and thank you all personally for your amazing support over the last five years,” said Beth-Ann G. Coller, executive director of Merck’s vaccine team in a note to the DTRA team. “This has truly been a journey and one that we are proud to have shared with our colleagues in DoD. Without the early and continued support of DTRA we would not be here today.”

DTRA continues to leverage its successful partnerships as the agency works to develop future countermeasures. DTRA and BARDA have active partnering agreements to develop vaccine and therapeutic medical countermeasures to address a diverse range of viral and bacterial infectious disease threats. Efforts will use a similar model to the one that supported development and approval of the EVD vaccine.

“As DTRA moves forward to new challenges, we will leverage continued utilization of the Ebola vaccine model, using a diverse range of ways that we can work with our academic, international, interagency and industrial partners through grants, contracts and other transaction authorities,” said Froude. “We have a proven paradigm on how to efficiently advance medical countermeasures working with our U.S. government partners in these endeavors.”

Disclaimer: Re-published content may be edited for length and clarity. Read original post.

You also may be interested in...

U.S. builds bonds in Papua New Guinea

Article
9/17/2019
Navy Lt. Austin Stokes, (right), and Air Force Maj. Nicole Smith (center), both dentists, talk to a patient at the Pacific Angel 19-4 health outreach site in Lae, Papua New Guinea. The health outreach site is comprised of five clinics including primary care, optometry, dental, physical therapy and pharmacy. (U.S. Air Force photo by Staff Sgt. Jerilyn Quintanilla)

This is the second Pacific Angel exercise conducted in Papua New Guinea

Recommended Content:

Global Health Engagement | Humanitarian Assistance and Disaster Relief | Global Health Engagement

Measles Myths: Vaccines Are Safe

Video
9/17/2019
Measles Myths: Vaccines Are Safe

Vaccine components have been rigorously tested for safety. Dr. Margaret Ryan, preventive medicine physician, debunks some myths about vaccinations.

Recommended Content:

Medical and Dental Preventive Care Fitness | Children's Health | Immunizations | Immunization Healthcare | Vaccine-Preventable Diseases | Measles-Mumps-Rubella

Measles Myths: Vaccines Do Not Cause Autism

Video
9/12/2019
Measles Myths: Vaccines Do Not Cause Autism

Vaccines that prevent measles do not cause autism. Dr. Margaret Ryan, preventive medicine physician, debunks some myths about vaccinations.

Recommended Content:

Medical and Dental Preventive Care Fitness | Children's Health | Immunizations | Immunization Healthcare | Vaccine-Preventable Diseases | Measles-Mumps-Rubella

Prevent to Protect: Rosarios

Video
8/30/2019
Prevent to Protect: Rosarios

10-year-old Tatiana Rosario has a weakened immune system as a result of her cancer treatment. Growing up, she and her family made sacrifices to keep her safe from disease.

Recommended Content:

Immunization Healthcare | Medical and Dental Preventive Care Fitness | Immunizations

Prevent to Protect: Analia

Video
8/30/2019
Prevent to Protect: Analia

Cancer left 5-year-old Analia Pages unable to get vaccinated. Her father, Master Sgt. Edward Pages, has to take extra steps to protect her from diseases she’s susceptible to.

Recommended Content:

Immunization Healthcare | Medical and Dental Preventive Care Fitness | Immunizations

Prevent to Protect: Immunization Awareness

Video
8/30/2019
Prevent to Protect: Immunization Awareness

Getting vaccinated not only protects yourself and your family from deadly diseases, but it also saves the lives to those who don’t have the immune system to fend for themselves. The Military Health System shares the stories of families with children who are at risk when others aren’t immunized.

Recommended Content:

Immunization Healthcare | Medical and Dental Preventive Care Fitness | Immunizations

Prevent to Protect: Barbara and Floriann

Video
8/30/2019
Prevent to Protect: Barbara and Floriann

Barbara’s son Floriann grew up with an immune dysregulation. A Uniformed Services University pathology professor, she’s experienced first hand the importance of vaccines.

Recommended Content:

Immunization Healthcare | Medical and Dental Preventive Care Fitness | Immunizations

DHA IPM 19-006: 2019–2020 Seasonal Influenza Vaccination Program (IVP)

Policy

This Defense Health Agency-Interim Procedures Memorandum (DHA-IPM), based on the authority of References (a) and (b), and in accordance with the guidance of References (c) through (o), implementing instructions, assigns responsibilities, and prescribes procedures for the seasonal influenza vaccination program. • This DHA-IPM cancels and reissues DHA-IPM 18-005. • This DHA-IPM is effective immediately and will expire 12 months from the date of issue.

Electronic Surveillance System for the Early Notification of Community-Based Epidemics (ESSENCE)

Fact Sheet
8/21/2019

This fact sheet describes the Electronic Surveillance System for the Early Notification of Community-Based Epidemics, or ESSENCE. ESSENCE is a global and Military Health System (MHS) monitoring capability for early detection of imminent health threats impacting force readiness for active duty service members.

Recommended Content:

Epidemiology and Analysis | Global Emerging Infections Surveillance | Solution Delivery Division

Vaccines: A public health success story

Article
8/7/2019
Tech Sgt. Joseph Anthony, medical technician with the 911th Aeromedical Staging Squadron, administers a vaccination to a member of the U.S. Army Reserve’s 336 Engineering Company Command and Control, Chemical Radiological and Nuclear Response Enterprise Team at the Pittsburgh International Airport Air Reserve Station, Pennsylvania, April 11, 2019. Department of Defense-issued vaccinations are used to prevent a variety of diseases that military members may encounter in the course of their duties. (U.S. Air Force photo by Joshua J. Seybert)

Maintaining a medically ready force is just one of many reasons to vaccinate

Recommended Content:

Medical and Dental Preventive Care Fitness | Immunizations | Immunization Healthcare | Vaccine-Preventable Diseases

CDC Pink Book

Publication
7/25/2019

Epidemiology and Prevention of Vaccine-Preventable Diseases - 13th Edition

Recommended Content:

Immunization Healthcare

DODI 6205.02 DOD Immunization Program

Policy

Establishes policy, assigns responsibilities, and provides procedures to establish a uniform DoD immunization program, in accordance with the authority in DoDD 6200.04 and DoD Instruction (DoDI) 1010.10.

Checklist: Best Practices for Vaccination Clinics Held at Satellite, Temporary, or Off-Site Locations

Publication
6/21/2019

A step-by-step guide to help clinic supervisors follow Centers for Disease Control and Prevention (CDC) and Department of Defense (DoD) guidelines while overseeing any nontraditional vaccination clinic setting.

Recommended Content:

Immunization Healthcare | Vaccine-Preventable Diseases | Vaccine Storage and Handling

Resolution of Payments to State Vaccine Programs

Congressional Testimony
4/17/2019

S. 3159, SAC Report for FY 2019, 115-290, Pg. 207

Recommended Content:

Immunization Healthcare

Shingrix Vaccine 2019

Infographic
3/26/2019
Fact Sheet about Shingrix, the FDA-approved vaccine to prevent shingles for healthy adults, age 50 and over

Infographic about Shingrix, the FDA-approved vaccine to prevent shingles for healthy adults, age 50 and over

Recommended Content:

Shingles | Medical and Dental Preventive Care Fitness | Immunizations
<< < ... 6 7 8 9 10  ... > >> 
Showing results 76 - 90 Page 6 of 12

DHA Address: 7700 Arlington Boulevard | Suite 5101 | Falls Church, VA | 22042-5101

Some documents are presented in Portable Document Format (PDF). A PDF reader is required for viewing. Download a PDF Reader or learn more about PDFs.